Identification of chemotherapeutic sensitizers

化疗增敏剂的鉴定

基本信息

项目摘要

Chemotherapeutic and radiation treatments cause a variety of genotoxic insults that lead to cell death in rapidly proliferating cancer cells. To survive genotoxic insults, cancer cells depend on multiple DNA repair pathways. Depending on the types of genotoxic insult, cells use a specific DNA repair pathway. When a DNA repair pathway is compromised, cancer cells become more sensitive to certain genotoxic insults. The identification of chemotherapeutic agents acting on compromised DNA repair pathways in cancer cells would result in more efficient treatment of cancer cells. Such agents are potential sensitizers for radiation therapy. We found that ATAD5 protein is stabilized in response to almost all genotoxic insults. Thus, we hypothesized that ATAD5 would be a good biomarker to detect genotoxic insults. We generated a cell line expressing the ATAD5-luciferase fusion protein and showed that the fusion protein is also stabilized in response to genotoxic insults. Previously, we used this novel cell-based quantitative high-throughput ATAD5-luciferase assay and successfully screened over 4,000 compounds from commercially available compound library as well as National Toxicology Program (NTP) library in collaboration with the NIH Chemical Genomics Center (NCGC) that is now part of National Center for Advancing Translational Science (NCATS) and National Institute of Environmental Health Sciences (NIEHS). In this pilot screen, we reported 22 antioxidants, including resveratrol, genistein, and baicalein induced DNA damage and resulted in cell death. Despite their genotoxic effects, resveratrol, genistein, and baicalein did not cause mutagenesis, which is a major side effect of conventional anti-cancer drugs. We therefore propose that resveratrol, genistein, and baicalein are attractive candidates for improved chemotherapeutic agents. Furthermore, we identified 200 compounds that stabilized ATAD5-luciferase in a dose dependent-manner from 300,000 compounds in the NIH chemical library in collaboration with the NCGC. To identify DNA repair pathways targeted by the genotoxic compounds, we used 8 isogenic human cell lines with targeted gene knockouts in specific DNA repair pathways. Approximately 200 compounds were tested in survival assays on these cells and group into sub-categories based on their IC50 to kill these cells. We found a small molecule that killed a mismatch repair deficient cancer cells and two small molecules that killed parp1 deficient cancer cells more efficiently. We are investigating whether these compounds can reduce tumor burden in vivo using xenograft mice as well as gene targeted mice models. Each compound will become a good tool to dissect molecular functions of different DNA repair pathways. In collaboration with NCATS, we also used the same ATAD5-luciferase cell line to identify compounds and siRNAs that inhibit the ATAD5 stabilization in response to genotoxic insults and have identified >80 compounds and >30 siRNAs. Genes identified from these siRNA screens will unveil the unknown mechanisms that inhibit proteolysis of DNA repair proteins in response to genotoxic insults. Two compounds from initial hits could be potential radiation and chemotherapeutic sensitizers in tumors. We found one compound inhibits general DNA damage response by destabilizing DNA damage response kinase(s). We are currently studying to identify targets of these compounds among genes identified from siRNA screening using bioinformatic analysis, epistatic analysis, as well as biochemical interactions.
化疗和放射治疗引起多种遗传毒性损伤,导致快速增殖的癌细胞的细胞死亡。为了在遗传毒性损伤中存活,癌细胞依赖于多种DNA修复途径。根据遗传毒性损伤的类型,细胞使用特定的DNA修复途径。当DNA修复途径受损时,癌细胞对某些遗传毒性损伤变得更加敏感。鉴定作用于癌细胞中受损DNA修复途径的化疗剂将导致癌细胞的更有效治疗。这类药物是放射治疗的潜在增敏剂。我们发现,ATAD 5蛋白是稳定的,几乎所有的遗传毒性的侮辱。因此,我们假设ATAD 5将是检测遗传毒性损伤的良好生物标志物。我们产生了表达ATAD 5-荧光素酶融合蛋白的细胞系,并显示融合蛋白也在响应于遗传毒性损伤时稳定。 之前,我们使用这种新型的基于细胞的定量高通量ATAD 5-荧光素酶测定,并与NIH化学基因组学中心(NCGC)合作,成功地从市售化合物库以及国家毒理学计划(NTP)库中筛选了4,000多种化合物,该中心现在是国家推进转化科学中心(NCATS)和国家环境健康科学研究所(NIEHS)的一部分。在这个试验性筛选中,我们报道了22种抗氧化剂,包括白藜芦醇、染料木素和黄芩素诱导DNA损伤并导致细胞死亡。 尽管它们具有遗传毒性作用,但白藜芦醇、染料木素和黄芩素不会引起诱变,而诱变是传统抗癌药物的主要副作用。因此,我们建议,白藜芦醇,染料木素,黄芩素是有吸引力的候选人,改善化疗药物。 此外,我们与NCGC合作,从NIH化学文库中的300,000种化合物中鉴定出200种以剂量依赖性方式稳定ATAD 5-荧光素酶的化合物。为了鉴定遗传毒性化合物靶向的DNA修复途径,我们使用了8个在特定DNA修复途径中具有靶向基因敲除的同基因人类细胞系。在对这些细胞的存活测定中测试了大约200种化合物,并基于它们杀死这些细胞的IC 50将其分组为亚类。我们发现一种小分子可以杀死错配修复缺陷的癌细胞,两种小分子可以更有效地杀死parp 1缺陷的癌细胞。我们正在研究这些化合物是否可以使用异种移植小鼠以及基因靶向小鼠模型来降低体内肿瘤负荷。每种化合物都将成为剖析不同DNA修复途径分子功能的良好工具。 与NCATS合作,我们还使用相同的ATAD 5-荧光素酶细胞系来鉴定响应于遗传毒性损伤而抑制ATAD 5稳定化的化合物和siRNA,并且已经鉴定了>80种化合物和>30种siRNA。从这些siRNA筛选中鉴定的基因将揭示抑制DNA修复蛋白对遗传毒性损伤的蛋白水解的未知机制。两个化合物从最初的命中可能是潜在的放射和化疗增敏剂在肿瘤中。 我们发现一种化合物通过使DNA损伤反应激酶不稳定来抑制一般的DNA损伤反应。我们目前正在研究,以确定这些化合物的靶基因之间的siRNA筛选使用生物信息学分析,上位性分析,以及生化相互作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kyungjae Myung其他文献

Kyungjae Myung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kyungjae Myung', 18)}}的其他基金

SEARCHING FOR PROTEIN INTERACTING WITH YEAST MPH1
寻找与酵母 MPH1 相互作用的蛋白质
  • 批准号:
    7602149
  • 财政年份:
    2007
  • 资助金额:
    $ 50.17万
  • 项目类别:
RAD5 INTERACTING PROTEIN SEARCH BY YEAST TWO HYBRID SCREENING
通过酵母二杂交筛选 RAD5 相互作用蛋白
  • 批准号:
    7420761
  • 财政年份:
    2006
  • 资助金额:
    $ 50.17万
  • 项目类别:
Genome Instability in Cancer Development
癌症发展中的基因组不稳定性
  • 批准号:
    6988951
  • 财政年份:
  • 资助金额:
    $ 50.17万
  • 项目类别:
Genome Instability in Cancer Development
癌症发展中的基因组不稳定性
  • 批准号:
    8750677
  • 财政年份:
  • 资助金额:
    $ 50.17万
  • 项目类别:
Genome Instability in Cancer Development
癌症发展中的基因组不稳定性
  • 批准号:
    8349992
  • 财政年份:
  • 资助金额:
    $ 50.17万
  • 项目类别:
Genome Instability in Cancer Development
癌症发展中的基因组不稳定性
  • 批准号:
    8149429
  • 财政年份:
  • 资助金额:
    $ 50.17万
  • 项目类别:
Genome Instability in Cancer Development
癌症发展中的基因组不稳定性
  • 批准号:
    8565537
  • 财政年份:
  • 资助金额:
    $ 50.17万
  • 项目类别:
Identification of chemotherapeutic sensitizers
化疗增敏剂的鉴定
  • 批准号:
    8565570
  • 财政年份:
  • 资助金额:
    $ 50.17万
  • 项目类别:
Genome Instability in Cancer Development
癌症发展中的基因组不稳定性
  • 批准号:
    8948363
  • 财政年份:
  • 资助金额:
    $ 50.17万
  • 项目类别:
Identification of chemotherapeutic sensitizers
化疗增敏剂的鉴定
  • 批准号:
    8948391
  • 财政年份:
  • 资助金额:
    $ 50.17万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 50.17万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 50.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 50.17万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 50.17万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 50.17万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 50.17万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 50.17万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 50.17万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 50.17万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 50.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了